A Study to Collect and Correlate the Data from Multiple Risk Assessments for Heart Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 16-002380
Sponsor Protocol Number: 16-002380
About this study
The purpose of this study is to collect and correlate the data from various cardiovascular risk asessments to successfully measure the risk of heart toxicity in patients receiving chemotherapy for breast cancer.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- Female
- ≥ 18 years of age
- Group 1
- All consented under IRB 1815-04 and agreed to the cardiac portion
- Have data that includes information such as echocardiograms (pre-treatment, during treatment and at end of treatment), endoPATs, and bloods collected as part of the cardiac study under this IRB
- Letter of support obtained from Dr. Olson for this information
- Group 2
- Newly diagnosed with HER-2 positive breast cancer
- Seen at Mayo Clinic Rochester
- Is planning to undergo anti-HER2 therapy with or without anthracycline within the Mayo Clinic Health System
- May have treatment at an outside facility if they are willing to return to Mayo Clinic for their cardiac monitoring
- Meet our inclusion criteria
Exclusion Criteria
- Left ventricular ejection fraction < 50%
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Joerg Herrmann, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available